Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Current Assets for 8 consecutive years, with $554.4 million as the latest value for Q1 2026.

  • Quarterly Current Assets fell 1.65% to $554.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $554.4 million through Feb 2026, down 1.65% year-over-year, with the annual reading at $606.8 million for FY2025, 2.03% down from the prior year.
  • Current Assets for Q1 2026 was $554.4 million at Nurix Therapeutics, down from $606.8 million in the prior quarter.
  • The five-year high for Current Assets was $619.4 million in Q4 2024, with the low at $251.0 million in Q1 2024.
  • Average Current Assets over 5 years is $403.5 million, with a median of $354.9 million recorded in 2022.
  • The sharpest move saw Current Assets dropped 24.49% in 2023, then surged 124.61% in 2025.
  • Over 5 years, Current Assets stood at $318.4 million in 2022, then fell by 7.21% to $295.5 million in 2023, then skyrocketed by 109.6% to $619.4 million in 2024, then dropped by 2.03% to $606.8 million in 2025, then fell by 8.64% to $554.4 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $554.4 million, $606.8 million, and $440.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.